BACKGROUND: Growth of selected castration-resistant prostate cancer (CRPC) cell lines and animal models can be repressed by reexposure to androgens. Low doses of androgens, however, can stimulate tumor growth. OBJECTIVE: We performed a phase 1 clinical trial to determine the safety of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer (CRMPC). DESIGN, SETTING, AND PARTICIPANTS: Patients with progressive CRMPC who had been castrate for at least 1 yr received three times the standard replacement dose of transdermal testosterone. INTERVENTION: Cohorts of 3-6 patients received testosterone for 1 wk, 1 mo, or until disease progression. MEASUREMENTS: Toxicities, androgen levels, prostate-specific antigen (PSA) assays, computed tomography (CT) scans, bone scintigraphy, positron emission tomography (PET) scans, and metastatic tumor biopsy androgen receptor levels were assessed. RESULTS AND LIMITATIONS: Twelve patients were treated-three in cohorts 1 and 2 and six in cohort 3. No pain flares were noted. One patient came off study because of epidural disease, which was treated with radiation. Average testosterone levels were within normal limits, although dihydrotestosterone (DHT) levels on average were supraphysiologic in cohort 3. One patient achieved a PSA decline of >50% from baseline. No objective responses were seen. For cohort 3, median time on treatment was 84 d (range: 23-247 d). CONCLUSIONS: We have demonstrated that patients with CRMPC can be safely treated in clinical trials using high-dose exogenous testosterone. Patients did not, on average, achieve sustained supraphysiologic serum testosterone levels. Future studies should employ strategies to maximize testosterone serum levels, use contemporary methods of identifying patients with androgen receptor overexpression, and utilize PSA Working Group II Consensus Criteria clinical trial end points. TRIAL REGISTRATION: ClinicalTrials.gov; NCT00006044.
BACKGROUND: Growth of selected castration-resistant prostate cancer (CRPC) cell lines and animal models can be repressed by reexposure to androgens. Low doses of androgens, however, can stimulate tumor growth. OBJECTIVE: We performed a phase 1 clinical trial to determine the safety of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer (CRMPC). DESIGN, SETTING, AND PARTICIPANTS: Patients with progressive CRMPC who had been castrate for at least 1 yr received three times the standard replacement dose of transdermal testosterone. INTERVENTION: Cohorts of 3-6 patients received testosterone for 1 wk, 1 mo, or until disease progression. MEASUREMENTS: Toxicities, androgen levels, prostate-specific antigen (PSA) assays, computed tomography (CT) scans, bone scintigraphy, positron emission tomography (PET) scans, and metastatic tumor biopsy androgen receptor levels were assessed. RESULTS AND LIMITATIONS: Twelve patients were treated-three in cohorts 1 and 2 and six in cohort 3. No pain flares were noted. One patient came off study because of epidural disease, which was treated with radiation. Average testosterone levels were within normal limits, although dihydrotestosterone (DHT) levels on average were supraphysiologic in cohort 3. One patient achieved a PSA decline of >50% from baseline. No objective responses were seen. For cohort 3, median time on treatment was 84 d (range: 23-247 d). CONCLUSIONS: We have demonstrated that patients with CRMPC can be safely treated in clinical trials using high-dose exogenous testosterone. Patients did not, on average, achieve sustained supraphysiologic serum testosterone levels. Future studies should employ strategies to maximize testosterone serum levels, use contemporary methods of identifying patients with androgen receptor overexpression, and utilize PSA Working Group II Consensus Criteria clinical trial end points. TRIAL REGISTRATION: ClinicalTrials.gov; NCT00006044.
Authors: A Manni; M Bartholomew; R Caplan; A Boucher; R Santen; A Lipton; H Harvey; M Simmonds; D White-Hershey; R Gordon Journal: J Clin Oncol Date: 1988-09 Impact factor: 44.544
Authors: Pat B Zanzonico; Ronald Finn; Keith S Pentlow; Yusuf Erdi; Bradley Beattie; Timothy Akhurst; Olivia Squire; Michael Morris; Howard Scher; Timothy McCarthy; Michael Welch; Steven M Larson; John L Humm Journal: J Nucl Med Date: 2004-11 Impact factor: 10.057
Authors: P Koivisto; J Kononen; C Palmberg; T Tammela; E Hyytinen; J Isola; J Trapman; K Cleutjens; A Noordzij; T Visakorpi; O P Kallioniemi Journal: Cancer Res Date: 1997-01-15 Impact factor: 12.701
Authors: Dana Rathkopf; Michael A Carducci; Michael J Morris; Susan F Slovin; Mario A Eisenberger; Roberto Pili; Samuel R Denmeade; Moshe Kelsen; Tracy Curley; Melinda Halter; Connie Collins; Martin Fleisher; Glenn Heller; Sharyn D Baker; Howard I Scher Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544
Authors: Changmeng Cai; Housheng Hansen He; Sen Chen; Ilsa Coleman; Hongyun Wang; Zi Fang; Shaoyong Chen; Peter S Nelson; X Shirley Liu; Myles Brown; Steven P Balk Journal: Cancer Cell Date: 2011-10-18 Impact factor: 31.743
Authors: Michael T Schweizer; Emmanuel S Antonarakis; Hao Wang; A Seun Ajiboye; Avery Spitz; Haiyi Cao; Jun Luo; Michael C Haffner; Srinivasan Yegnasubramanian; Michael A Carducci; Mario A Eisenberger; John T Isaacs; Samuel R Denmeade Journal: Sci Transl Med Date: 2015-01-07 Impact factor: 17.956
Authors: Mandeep Singh; Ruchi Jha; Jonathan Melamed; Ellen Shapiro; Simon W Hayward; Peng Lee Journal: Am J Pathol Date: 2014-08-01 Impact factor: 4.307